HDAC9 and hepatocellular carcinoma: Recent pharmacological study using santacruzamate A, in combination with other HDAC inhibitors, such as HDAC1 inhibitor, tacedinaline, HDAC1/2 common inhibitor, romidepsin (FK228) and global HDAC inhibitor, vorinostat (SAHA), to treat hepatocellular carcinoma (HCC) was reported [56].